Henry J. Smith

Henry J. Smith is the Chief Technology Officer and has over 30 years of experience managing medical laboratories and biotechnology companies. Dr. Smith is at the forefront of research in cancer diagnostics and was one of the pioneers in developing the ever-first test for CEA (carcinoembryonic antigen), a cancer marker that still is utilized as a premier cancer diagnostic test. His research has led to the development of other novel assays such as estrogen receptors, HLA typing protocols, and Acetylcholine receptors. His work in allergy testing led to the first report of the normal range for IgE. Dr. Smith has several patents in the diagnostic field and has been instrumental in developing the methodology for the rapid assay for glycated albumin that underlies the Epinex G1A test. He has extensive expertise in determining experimental design, clinical validity, accuracy, reproducibility, stability, and toxicity.